RecruitingNot Applicable

Nicotinamide Adenine Dinucleotide (NAD+) Metabolism in Human Brown Adipose Tissue

Finland68 participantsStarted 2024-11-20

Plain-language summary

A fully functional brown fat helps maintain a healthy weight and decreases the risk of metabolic diseases such as type II diabetes (T2DM). Unfortunately, in human adults, the functionality of brown fat declines with age, and it is one of the reasons for gaining unhealthy weight, particularly around the waistline (central obesity). Currently, scientists do not clearly understand the reasons for the decline in brown fat functionality. It is possible that the decline in the availability of the molecule Nicotinamide Adenine Dinucleotide (NAD+), which is central to several metabolic processes, plays a role in the decline in brown fat metabolism. This project will clarify whether NAD+-based molecular-targeted therapies for the enhancement of whole-body insulin sensitivity and brown fat metabolism will be successful in adult humans, which will eventually be an important target for reducing the development of obesity and its comorbidities such as T2DM.

Who can participate

Age range30 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Willingness to provide informed consent to participate in the BATNAD study * Must be able to read and speak English/Finnish/Swedish well enough to completely understand the instructions and provide informed consent * Age 30-55 (sedentary lifestyle) * BMI = 18-25 kg/m2 (normal-weight subjects) * BMI ≥ 28 kg/m2 and waist circumference more than 100 cm in men and more than 90 cm in women (subjects with obesity) Exclusion Criteria: * Inability to have PET/CT (claustrophobia, metal implants, recent tattoo including metal components, weight \> 200 kg) * Pregnancy and pregnancy related conditions (postpartum/lactation during the last 12 months, or planning to become pregnant soon) * Major alterations in the menstrual cycle (e.g., amenorrhea) * Use of nicotine based products * Hypo- or hyper- thyroidism (medical history, TSH, T3 or T4 levels out of the normal range) * Diabetes mellitus (fasting Hb1Ac \>6.5% or fasting glycaemia\> 7.0 mmol/) * Abnormal oral glucose tolerance test (2h OGTT \> 11.1 mmol/L) * Hypertension (blood pressure \> 160/100 mmHg) * Abnormal cardiovascular status (arrhythmia and/or long QTc in ECG, abnormal cardiac murmur, previous history of cardiovascular disease) * Abnormal coagulopathy (e.g., clotting abnormality) * Malignancies * Immunological, autoimmune and primary/secondary immunodeficiency disorders (including or not any active treatment) * Virus or bacterial infection (both asymptomatic and symptomatic picture) wit…

What they're measuring

Whole-body Insulin Sensitivity

Timeframe: 6 months

Trial details

NCT IDNCT06627868

SponsorUniversity of Turku

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-08-31

Contact for this trial

Mueez U-Din, PhD

+358-417027723 mueez.udin@utu.fi